Inotuzumab ozogamicin monotherapy (adult R/R B-ALL, CD22+)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-INOTUZUMAB-OZOGAMICIN |
|---|
| ID | REG-INOTUZUMAB-BALL-ADULT-RR |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-INOVATE-KANTARJIAN-2016 SRC-NCCN-ALL-2025 |
Notes
CD22-directed antibody-drug conjugate (calicheamicin payload) for adult R/R Ph-negative or Ph-positive B-ALL. INO-VATE ALL (Phase III, n=326, inotuzumab vs investigator's-choice intensive chemo, R/R B-ALL) — CR/CRi 80.7% vs 29.4% (p<0.001); MRD-negative CR 78.4%; mPFS 5.0 vs 1.8 mo; mOS 7.7 vs 6.7 mo (HR 0.77, p=0.04). Bridge to allo-HSCT — 41% vs 11% transitioned. BOXED WARNING: hepatotoxicity / VOD/SOS, especially post-HSCT with dual-alkylator conditioning. Limit to ≤2 cycles pre-HSCT. Combination strategies (mini-hyper-CVD + InO ± blinatumomab — Jabbour / MD Anderson) are separate regimen entities. Pending Co-Lead sign-off.
Used By
No reverse references found in the YAML corpus.